1.52
Precedente Chiudi:
$1.515
Aprire:
$1.52
Volume 24 ore:
1.01M
Relative Volume:
4.15
Capitalizzazione di mercato:
$39.98M
Reddito:
$4.99M
Utile/perdita netta:
$-28.29M
Rapporto P/E:
-1.4438
EPS:
-1.0528
Flusso di cassa netto:
$-36.20M
1 W Prestazione:
-2.56%
1M Prestazione:
+0.66%
6M Prestazione:
+23.58%
1 anno Prestazione:
-7.88%
Lava Therapeutics Nv Stock (LVTX) Company Profile
Nome
Lava Therapeutics Nv
Settore
Industria
Telefono
31 6 3000 3035
Indirizzo
YALELAAN 62, UTRECHT
Confronta LVTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
LVTX
Lava Therapeutics Nv
|
1.52 | 40.25M | 4.99M | -28.29M | -36.20M | -1.0528 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2022-10-25 | Iniziato | H.C. Wainwright | Buy |
2021-04-19 | Iniziato | JP Morgan | Overweight |
2021-04-19 | Iniziato | Jefferies | Buy |
2021-04-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lava Therapeutics Nv Borsa (LVTX) Ultime notizie
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 1% Following Insider Selling - Defense World
Gilde healthcare sells LAVA Therapeutics (LVTX) shares for $718k By Investing.com - Investing.com Canada
Gilde healthcare sells LAVA Therapeutics (LVTX) shares for $718k - Investing.com
How LAVA Therapeutics N.V. stock valuations compare to rivalsFed Meeting & Real-Time Volume Analysis Alerts - newser.com
Price momentum metrics for LAVA Therapeutics N.V. explainedJuly 2025 Spike Watch & Low Risk High Win Rate Stock Picks - newser.com
What indicators show strength in LAVA Therapeutics N.V.Gap Down & Entry and Exit Point Strategies - newser.com
Can LAVA Therapeutics N.V. hit a new high this monthJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Will LAVA Therapeutics N.V. stock go up soonQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
LAVA Therapeutics N.V. stock prediction for this weekDollar Strength & Weekly Stock Performance Updates - newser.com
LAVA Therapeutics N.V. Stock (LVTX) Opinions on Insider Sales and Acquisition Delays - Quiver Quantitative
Gilde Healthcare sells LAVA Therapeutics (LVTX) shares for $197,898 By Investing.com - Investing.com South Africa
Gilde Healthcare sells LAVA Therapeutics (LVTX) shares for $197,898 - Investing.com
LAVA Therapeutics N.V. recovery potential after sell offPortfolio Return Report & Safe Entry Zone Identification - newser.com
Can LAVA Therapeutics N.V. rally from current levelsJuly 2025 Setups & High Yield Equity Trading Tips - newser.com
Is LAVA Therapeutics N.V. forming a reversal patternLayoff News & Expert Approved Momentum Trade Ideas - newser.com
Is LAVA Therapeutics N.V. (4PKB) stock overpriced at current multiplesJuly 2025 Momentum & Low Drawdown Momentum Ideas - newser.com
Why LAVA Therapeutics N.V. stock remains resilientTrade Signal Summary & High Win Rate Trade Tips - newser.com
Published on: 2025-10-05 06:23:52 - newser.com
Analyzing recovery setups for LAVA Therapeutics N.V. investorsJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Measuring LAVA Therapeutics N.V.’s beta against major indicesQuarterly Trade Report & High Conviction Investment Ideas - newser.com
Will LAVA Therapeutics N.V. outperform the marketJuly 2025 Setups & Entry Point Confirmation Signals - newser.com
What candlestick patterns are forming on LAVA Therapeutics N.V.Weekly Trend Recap & Daily Oversold Bounce Ideas - newser.com
How LAVA Therapeutics N.V. stock performs in rate cut cyclesJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
XOMA Royalty extends tender offer deadline for LAVA Therapeutics By Investing.com - Investing.com Australia
Shay Capital LLC Acquires Significant Stake in LAVA Therapeutics NV - GuruFocus
LAVA Therapeutics Extends Tender Offer Deadline - TipRanks
XOMA Royalty extends tender offer deadline for LAVA Therapeutics - Investing.com India
XOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025 - Quiver Quantitative
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewswire
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - Benzinga
75% CVR: XOMA Royalty Extends Tender Offer for LAVA, Extended to Oct. 17 - Stock Titan
What drives LAVA Therapeutics NV stock priceBollinger Bands Signals & High-Risk, High-Reward? We Find the Winners - earlytimes.in
LAVA Therapeutics Postpones EGM for XOMA Deal - MSN
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - GlobeNewswire
LAVA Therapeutics Cancels Extraordinary General Meeting to Finalize XOMA Royalty Acquisition Details - Quiver Quantitative
Biotech Deal Update: LAVA Therapeutics Postpones XOMA Acquisition Vote to Address Cash Position - Stock Titan
Lava Therapeutics Nv Azioni (LVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lava Therapeutics Nv Azioni (LVTX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Cooperatieve Gilde Healthcare | 10% Owner |
Oct 13 '25 |
Sale |
1.54 |
47,686 |
73,436 |
5,246,492 |
Cooperatieve Gilde Healthcare | 10% Owner |
Oct 10 '25 |
Sale |
1.55 |
49,869 |
77,297 |
5,294,178 |
Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
Versant Venture Capital VI, L. | 10% Owner |
Sep 16 '25 |
Sale |
1.53 |
307,707 |
471,776 |
3,099,450 |
Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
226,726 |
337,640 |
761,661 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):